| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a new heterocyclic compound of general formula (I)or its stereoisomer, or its pharmaceutically acceptable salt, wherein Q means oxadiazol, thiadiazole or tetrazole; Rmeans: (b) (CO)-Ror (c) COOR, n=0 or 1; Rmeans SOM, M means hydrogen or cation; Rmeans: (a) C-C-alkyl optionally substituted by one or more substitute independently specified in halogen, NRR, heterocyclyl or aryl, (b) NRR, (c) CONRR, (d) aryl, (e) heterocyclyl, or (f) heteroaryl optionally substituted by CONRR, Rmeans (a) hydrogen, or (b) C-C-alkyl; each Rand Rindependently means (a) hydrogen or (b) Rand Rare coupled together to form a four- to seven-merous ring, wherein cycloalkyl represents 3-7-merous cyclic hydrocarbon radical; heterocyclyl represents 4-7-merous cycloalkyl group containing one or more heteroatoms specified in nitrogen, oxygen or sulphur; aryl represents monocyclic or polycyclic hydrocarbon containing 6-14 atoms in the ring; heteroaryl represents monocyclic or polycyclic heteroaryl, wherein one or more carbon atoms are substituted by heteroatoms specified in nitrogen, oxygen or sulphur. The invention also refers to a pharmaceutical composition based on the compound of formula (I) and a method for preventing or treating a bacterial infection based on using the compound of formula (I).EFFECT: produced are the new heterocyclic compounds effective in treating bacterial infections.27 cl, 4 tbl, 28 ex |
